Nurix, Inc. Names Arthur T. Sands, M.D., Ph.D., Chief Executive Officer« back

Nurix Expands Leadership Team with Appointment of Pierre Beaurang, Ph.D., as Vice President, Business and Corporate Development

SAN FRANCISCO–(BUSINESS WIRE)–Nurix, Inc., a leader in discovering and developing therapies that modulate the ubiquitin proteasome system (UPS), announced today the appointment of Arthur T. Sands, M.D., Ph.D., as chief executive officer. Dr. Sands succeeds interim chief executive officer Mark A. Goldsmith, M.D., Ph.D., a partner at Third Rock Ventures, who will continue service to the company as chairman of its board of directors. In conjunction with this appointment, Nurix also named Pierre Beaurang, Ph.D., vice president, business and corporate development.

“I am delighted to join Nurix at this point in the company’s evolution as it establishes a broadly applicable platform in drug discovery based on its innovative research on the selective modulation of ubiquitin ligases for breakthrough applications in cancer and other diseases,” said Dr. Sands. “Nurix has already built a strong foundation with world-renowned founders, collaborators and an outstanding scientific team. I would like to thank Mark for his leadership since the inception of the Company, and look forward to working with him, Nurix’s board of directors and its growing team on behalf of patients with life-threatening diseases.”

Prior to joining Nurix, Dr. Sands co-founded Lexicon Pharmaceuticals (Nasdaq: LXRX) and served as president, chief executive officer and a director since 1995. At Lexicon, Dr. Sands pioneered the development of large-scale gene knockout technology for use in drug discovery and guided the evolution of Lexicon from a research-stage company to a drug development company, catalyzed by numerous alliances with Bristol Myers Squibb, Takeda and Genentech, and generating more than $450 million in revenue. Lexicon’s independently developed product portfolio, now approaching late stage development and commercialization, includes small molecules directed to novel targets for treatment of carcinoid syndrome, type 1 diabetes and type 2 diabetes. Dr. Sands serves as adjunct professor in the Department of Human and Molecular Genetics at Baylor College of Medicine. He has also published many scientific and medical articles and is an inventor on numerous patents related to the discovery of human genes and their use in the development of new therapies. Dr. Sands holds an M.D. and a Ph.D. from Baylor College of Medicine and a B.A. in economics and political science from Yale University.

Dr. Beaurang brings to Nurix nearly 15 years of business and operational experience in the biotechnology industry. Prior to joining Nurix, Dr. Beaurang was part of the founding team of Five Prime Therapeutics (Nasdaq: FPRX), contributing to the conceptualization, creation and implementation of the company plan and serving in multiple operational and business development roles of increasing responsibility through his appointment as executive director of business development. Dr. Beaurang negotiated several product and platform-related transactions with global pharmaceutical firms and major biotechnology companies on behalf of Five Prime Therapeutics, including GlaxoSmithKline, UCB and Bristol Myers Squibb, helping secure an aggregate $270 million in near term revenues and more than $2.4 billion in potential milestone payments. Dr. Beaurang holds a Ph.D. in molecular and cell biology from University of California, Berkeley and conducted postdoctoral research at the University of California, San Francisco. He holds B.A. and M.A. degrees in biology and biotechnology, respectively, from Boston University.

About Nurix

Nurix, Inc. is a leader in discovering and developing a new class of drugs that work by modulating the protein regulation machinery of the cell through the ubiquitin proteasome system (UPS). The UPS is a regulatory pathway that controls protein stabilization and degradation, a function vital to the healthy life of a cell, and presents therapeutic opportunities in multiple disease areas, including oncology and immno-oncology. Nurix’s state-of–the-art product engine leverages a deep mechanistic understanding of the UPS to deliver effective small molecule drug candidates with the potential to make a dramatic difference for patients. Nurix was founded by internationally recognized experts in the ubiquitin proteasome field and is funded by leading life science investors, Third Rock Ventures and The Column Group. The company is headquartered in San Francisco, California. For more information, please visit www.nurix-inc.com.

Contacts

Pure Communications, Inc.
Katie Engleman, 910-509-3977
katie@purecommunicationsinc.com